The genetic landscape of diffuse large B-cell lymphoma.

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in the western world, is an aggressive disease that remains incurable in approximately 30% of patients. Over the past decade, the rapid expansion of sequencing technologies allowing the genome-wide assessment of genomic and transcriptional changes has revolutionized our understanding of the genetic basis of DLBCL by providing a comprehensive and unbiased view of the genes/pathways that are disrupted by genetic alterations in this disease, and may contribute to tumor initiation and expansion. These studies uncovered the existence of several previously unappreciated alterations in key cellular pathways that may also influence treatment outcome. Indeed, a number of newly identified genetic lesions are currently being explored as markers for improved diagnosis and risk stratification, or are entering clinical trials as promising therapeutic targets. This review focuses on recent advances in the genomic characterization of DLBCL and discusses how information gained from these efforts has provided new insights into its biology, uncovering potential targets of prognostic and therapeutic relevance.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  Adrien B. Larsen,et al.  Loss of signaling via Gα13 in germinal center B cell-derived lymphoma , 2014, Nature.

[3]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[4]  L. Ferrarini,et al.  Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. , 2013, The Journal of clinical investigation.

[5]  K. Basso,et al.  MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma , 2013, Nature Immunology.

[6]  David I Heiman,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2013, Nature.

[7]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[8]  Steven J. M. Jones,et al.  Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. , 2013, Blood.

[9]  Ash A. Alizadeh,et al.  Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. , 2012, Blood.

[10]  Steven J. M. Jones,et al.  Recurrent targets of aberrant somatic hypermutation in lymphoma , 2012, Oncotarget.

[11]  K. Rajewsky,et al.  MYC is essential for the formation and maintenance of germinal centers , 2012, Nature Immunology.

[12]  M. Nussenzweig,et al.  The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry , 2012, Nature Immunology.

[13]  M. Nussenzweig,et al.  Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. , 2012, Blood.

[14]  Stefano Monti,et al.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.

[15]  K. Basso,et al.  Roles of BCL6 in normal and transformed germinal center B cells , 2012, Immunological reviews.

[16]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[17]  Michele Pagano,et al.  FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas , 2012, Nature.

[18]  Govind Bhagat,et al.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.

[19]  Christian Steidl,et al.  The molecular pathogenesis of primary mediastinal large B-cell lymphoma. , 2011, Blood.

[20]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[21]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[22]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[23]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[24]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[25]  J. Kutok,et al.  Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. , 2010, Cancer cell.

[26]  L. Pasqualucci,et al.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.

[27]  Jan Delabie,et al.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.

[28]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[29]  K. Basso,et al.  BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma , 2009, Proceedings of the National Academy of Sciences.

[30]  L. Pasqualucci,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[31]  S. Ogawa,et al.  Frequent inactivation of A20 in B-cell lymphomas , 2009, Nature.

[32]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[33]  Jan Delabie,et al.  Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.

[34]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[35]  L. Staudt,et al.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.

[36]  M. Shipp,et al.  BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. , 2007, Blood.

[37]  K. Basso,et al.  A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. , 2007, Cancer cell.

[38]  L. Staudt,et al.  Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma , 2007, The Journal of experimental medicine.

[39]  W. Chan,et al.  Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. , 2006, Blood.

[40]  Stefano Monti,et al.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.

[41]  Peter Cresswell,et al.  Mechanisms of MHC class I‐restricted antigen processing and cross‐presentation , 2005, Immunological reviews.

[42]  Qiong Shen,et al.  Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. , 2005, Cancer cell.

[43]  Ryan T. Phan,et al.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells , 2004, Nature.

[44]  T. Golub,et al.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.

[45]  Matthew T Wheeler,et al.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses , 2004, Nature Immunology.

[46]  M. Nussenzweig,et al.  AID Is Required for c-myc/IgH Chromosome Translocations In Vivo , 2004, Cell.

[47]  M. Thome.  CARMA1, BCL-10 and MALT1 in lymphocyte development and activation , 2004, Nature Reviews Immunology.

[48]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[49]  K. Calame,et al.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.

[50]  L. Staudt,et al.  Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.

[51]  Katia Basso,et al.  Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. , 2003, Blood.

[52]  A. Naganuma,et al.  Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[54]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[55]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[56]  Riccardo Dalla-Favera,et al.  Mechanisms of chromosomal translocations in B cell lymphomas , 2001, Oncogene.

[57]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[58]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[59]  A. Fischer,et al.  Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2) , 2000, Cell.

[60]  Ash A. Alizadeh,et al.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[62]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[63]  L. Pasqualucci,et al.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  U. Storb,et al.  Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. , 1998, Science.

[65]  K Offit,et al.  Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. , 1993, Science.

[66]  L. Staudt,et al.  Diffuse large B-cell lymphoma—treatment approaches in the molecular era , 2014, Nature Reviews Clinical Oncology.

[67]  M. Nussenzweig,et al.  Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes , 2011, Nature Immunology.

[68]  Riccardo Dalla-Favera,et al.  Germinal centres: role in B-cell physiology and malignancy , 2008, Nature Reviews Immunology.

[69]  L. Pasqualucci,et al.  AID is required for germinal center–derived lymphomagenesis , 2008, Nature Genetics.

[70]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.